According to CoinMeta, and based on news from Novo Nordisk China, Novo Nordisk has announced that the compensation for the patent term of its drug related to the indication of NovoTetra® (semaglutide injection) for chronic kidney disease ( CKD ) has been approved by the National Intellectual Property Administration. As a result, the protection period for the relevant indication patent has been extended by 5 years to March 2031.